

MELANOMA DISEASE SITE COMMITTEE MEETING

SUNDAY MAY 1, 2022, 11:00 AM – 1:00 PM ET

CO-CHAIRS : MARCUS BUTLER AND IAN WATSON
SENIOR INVESTIGATOR: JANET DANCEY

CME Credits:

Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.

Learning Objectives:

- To interpret and address, through clinical and translational research, the disease burden associated with malignant melanoma in Canada.
- To summarize recent developments in the understanding of molecular biology and therapeutics as these relate to malignant melanoma
- To cite and analyze recent results of clinical studies conducted by or in collaboration with CCTG
- To interpret and apply new clinical trial methodologies in the field of clinical research

11:00 am	Welcome	
11:00 am	Update on action items from last Meeting	Marcus Butler Ian Watson
11:05 am	CCS Grant Update and TFRI MOHCC	Marcus Butler Ian Watson
11:15 am	Updates on ongoing trials <ul style="list-style-type: none"> • MEC6 • ME13 • ME15 	Danielle Vicus Xinni Song Frances Wright
CTC Reviewed/Approved Trial Proposals		
11:35 am	A randomized phase III trial of adjuvant treatment guided by response post neoadjuvant therapy for clinical stage III melanoma	Xinni Song
12:05 pm	Neoadjuvant BCC	Vanessa Bernstein
Updates from the Working Groups		
12:20 pm	IND/Metastatic	Michael Ong
12:35 pm	Surveillance Melanoma Decision Dx Imaging Surveillance Trial (Mist)	Carolyn Nessim
12:50 pm	Polls Other business Next Meeting	Marcus Butler Ian Watson
1:00 pm	Meeting Adjourned	Marcus Butler Ian Watson